following a full submission:
solriamfetol (Sunosi®) is not recommended for use within NHSScotland.
Indication under review: to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).
Solriamfetol, compared with placebo, reduced EDS in adults with OSA who were currently using or had previously tried a primary OSA therapy.
The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- solriamfetol (Sunosi)
- SMC ID:
- SMC2419
- Indication:
To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).
- Pharmaceutical company
- Jazz Pharmaceuticals
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 March 2022